US Patent

US9181192 — Deuterated CFTR potentiators

Method of Use · Assigned to Concert Pharmaceuticals Inc · Expires 2032-05-17 · 6y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects deuterated CFTR potentiators and their compositions for use in treating diseases and conditions that respond to CFTR potentiators.

USPTO Abstract

This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4094`	—
`U-4094`	—

Patent Metadata

Patent number: US9181192
Jurisdiction: US
Classification: Method of Use
Expires: 2032-05-17
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Concert Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.